FCPM III SERVICES B V
Q2 2026 Form 13-F
NAARDEN
CIK 0002013410
· Institutional investment manager
Consolidated report · includes
3 managers
since Q4 2023
$750.4M Reported Value Total
Reported value
$750.4M
Quarter over quarter
+5.7%
Holdings
11
Top-10 concentration
99.9%
Filing Structure
Reports holdings for
- Forbion Growth Management B.V. (not a 13F filer in our records) · File #028-24009 · since Q4 2023
- Forbion IV Management B.V. (not a 13F filer in our records) · File #028-24010 · since Q4 2023
- Forbion Growth Management III B.V. (not a 13F filer in our records) · File #028-26443 · since Q1 2026 · declared by one filing
- Forbion Growth Management III B.V. (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
- Forbion Growth Management II B.V. (not a 13F filer in our records) · File #028-25150 · Q1 2025 – Q3 2025 · declared by one filing
- Forbion Growth Management II B.V. (not a 13F filer in our records) · Q4 2024 – Q4 2024 · declared by one filing
Key People
Named on the latest Form 13-F filing — not necessarily an owner
M.a. Van Osch And G.j. Mulder
Directors
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $750.4M |
| Positions | 11 |
| Change in reported value | +3.9% |
| New positions | 1 |
| Exited positions | 0 |
| Position turnover | 9.1% |
| Top-10 concentration | 99.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
15 | $1.1B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
11 | $750.4M |
|
Q1 2026 13F
Filed May 15, 2026
|
10 | $722.2M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
10 | $762.9M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
9 | $500.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
8 | $369.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
7 | $413.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
8 | $592.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
7 | $582.3M |
|
Q2 2024 13F
Filed Aug 8, 2024
|
7 | $678.1M |
|
Q1 2024 13F
Filed May 3, 2024
|
6 | $707.3M |
|
Q4 2023 13F
Filed Mar 7, 2024
|
6 | $339.4M |
Top 11 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | NAMS NEWAMSTERDAM PHARMA COMPANY | $287.7M | 38.34% |
| 2 | MPLT MAPLIGHT THERAPEUTICS INC | $115.6M | 15.41% |
| 3 | DYN DYNE THERAPEUTICS INC | $85.5M | 11.39% |
| 4 | VOR VOR BIOPHARMA INC | $75.8M | 10.1% |
| 5 | GLTO DAMORA THERAPEUTICS INC | $63.5M | 8.46% |
| 6 | REPL REPLIMUNE GROUP INC | $31.1M | 4.14% |
| 7 | CBIO CRESCENT BIOPHARMA INC. | $30.2M | 4.02% |
| 8 | AURA AURA BIOSCIENCES INC | $28.8M | 3.84% |
| 9 | ENGN ENGENE HOLDINGS INC | $16.7M | 2.22% |
| 10 | BCYC BICYCLE THERAPEUTICS PLC | $14.7M | 1.96% |
| 11 | ENGNW ENGENE HOLDINGS INC | $834.4K | 0.11% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.